$ cat ./records/gates-foundation-funds-nigeria-cdc-serosurveillance-regional-hub-2024.txt
Gates Foundation Funds Nigeria CDC Serosurveillance Regional Hub
[RECORD.TXT] · cat --full
The Gates Foundation committed $800,000 over 29 months to Nigeria's Centre for Disease Control and Prevention to establish a Multiplex Bead Assay Serosurveillance Regional Hub and support South-to-South technology transfer across the West African sub-region. The hub conducts serological surveillance for malaria, neglected tropical diseases, pneumonia, and pandemic-prone pathogens, generating population-level immunity data that governments use to refine vaccination strategies and detect silent transmission ahead of outbreaks.
Source: https://www.gatesfoundation.org/about/committed-grants/2024/12/inv-060111
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Breakthrough Energy Ventures Raises $839 Million Fund III with Food and Agriculture Focus
Next →
Breakthrough Energy Catalyst Invests $40 Million in Deep Sky Carbon Removal
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.